<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147926">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01808287</url>
  </required_header>
  <id_info>
    <org_study_id>2012-07</org_study_id>
    <nct_id>NCT01808287</nct_id>
  </id_info>
  <brief_title>Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve</brief_title>
  <acronym>SAPIEN3</acronym>
  <official_title>Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medstar Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Cardiovascular Research  Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and device success of the Edwards SAPIEN 3
      Transcatheter Heart Valve (S3 THV) and the Edwards Commander and Certitude Delivery Systems
      in patients with symptomatic, severe aortic stenosis who are indicated for aortic valve
      replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, prospective, multi-center safety and device success study. One
      hundred fifty (150) patients are planned to be enrolled at up to 15 participating
      investigational centers in Europe and Canada.  Patient participation will last for a minimum
      of 5 years.  Patients will be assessed at the following intervals: baseline, hospital
      discharge, 30 days, 1 year and annually thereafter for a minimum of 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>All-cause mortality rate</measure>
    <time_frame>30 days post-index procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>NAP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>device success(VARC II) safety endpoints(VARC II) echocardiography endpoints(VARCII)</measure>
    <time_frame>Discharge or 72 hours (whichever is longer), 30 days, 1 and 5 years post-index procedure.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>device success
absence of procedural mortality AND correct positioning of a single THV and intended performance of the THV
safety endpoints
composite of mortality, and major complications including THV-related dysfunction major bleeds MI new conduction abnormality new onset of AF time-related valve safety compo-site of valve structural deterioration composite of all-cause mortality, all stroke, re-hospitalization for valve-related symptoms or worsening CHF rehospitalization for valve cause NYHA class 6 MWT QoL Hospital length of stay
echocardiography endpoints
PVL &amp; total valve regurgitation prostetic valve dysfunction IEOA mean aortic valve gradient structural valve deterioration LVEF</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Aortic Valve Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards SAPIEN 3 Transcatheter Heart Valve</intervention_name>
    <description>The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (interme-diate or higher operable risk) with severe aortic stenosis re-quiring aortic valve replacement (AVR).</description>
    <other_name>TAVR</other_name>
    <other_name>TAVI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Severe symptomatic calcific aortic valve stenosis with:

               1. High surgical risk: STS Score ≥ 8 or EuroSCORE ≥ 15 (first 50 patients),

               2. Intermediate surgical risk: STS Score ≥ 4 or EuroSCORE ≥ 10 (subse-quent 100
                  patients).

          2. Age ≥ 75 years.

          3. NYHA ≥ II

          4. AVA&lt; 1cm2 and mean gradient &gt; 40mmHg

          5. Heart team (including examining cardiac surgeon) agrees on eligibility including
             assessment that TAVR is appropriate

          6. Study patient has provided written informed consent to comply with all of the study
             procedures and follow-up visits

        Exclusion Criteria:

          1. Non-calcified aortic valve

          2. Acute myocardial infarction ≤ 30 days before the intended treatment

          3. Untreated clinically significant coronary artery disease requiring revascularization.

          4. Aortic valve is a congenital unicuspid or congenital bicuspid valve.

          5. Mixed aortic valve disease (with predominant aortic regurgitation)

          6. Preexisting bioprosthetic valve or ring in any position

          7. Leukopenia, anemia, thrombocytopenia

          8. Hypertrophic cardiomyopathy with or without obstruction

          9. Severe ventricular dysfunction with LVEF &lt; 20%

         10. Echocardiographic evidence of intracardiac mass, thrombus or vegetation

         11. Active upper GI bleeding within 90 days prior to procedure

         12. known contraindication or hypersensitivity to all anticoagulation regimens, or
             inability to be anticoagulated for the study procedure

         13. Native aortic annulus size :

               1. &lt; 18 mm or &gt; 25 mm as measured by TEE, 23 and 26mm valves

               2. &gt; 27mm as measured by TEE, 29mm valve

               3. &lt; 16mm as measured by TEE, 20mm valve

         14. Clinically (by neurologist) or neuroimaging confirmed stroke or TIA within 90 days of
             the procedure

         15. Renal insufficiency (creatinine &gt; 3.0 mg/dL) and/or renal replacement therapy at the
             time of screening

         16. Estimated life expectancy &lt; 24 months

         17. Expectation that patient will not improve despite treatment of aortic stenosis

         18. Currently participating in an investigational drug or another device study

         19. Active bacterial endocarditis within 180 days of procedure

         20. Known hypersensitivity to contrast media, nitinol (nickel or titanium)

         21. Any neurologic disease which severely affects the ability to walk or perform everyday
             activities

         22. Senile dementia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jodi Akin, MSN</last_name>
    <phone>949-250-2730</phone>
    <email>jodi_akin@edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ishen Merioua, MD</last_name>
    <phone>+41 44 787 4456</phone>
    <email>ihsen_merioua@edwards.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1 Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Webb, MD</last_name>
      <phone>+1 604 806 8902</phone>
      <email>webb@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>John Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Eltchaninoff, MD</last_name>
      <phone>+33 2 32 88 86 25</phone>
      <email>helene.eltchaninoff@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Helene Eltchaninoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Dumonteil, MD</last_name>
      <phone>+33561323548</phone>
      <email>dumonteil.n@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas Dumonteil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Heartcenter</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Thomas Walther, MD</last_name>
      <phone>+49 6032 996 2501</phone>
      <email>T.Walther@kerckhoff-klinik.de</email>
    </contact>
    <investigator>
      <last_name>Prof. Dr. Thomas Walther, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Thielmann, MD</last_name>
      <email>Matthias.Thielmann@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Thielmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitares Herzzentrum Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrick Treede, MD</last_name>
      <phone>+49 40 7410 58949</phone>
      <email>treede@uke.de</email>
    </contact>
    <investigator>
      <last_name>Hendrick Treede, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtisches Klinikum Kalsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Schymik, MD</last_name>
      <phone>+49 721 974 29 10</phone>
      <email>gerhard.schymik@klinikum-karlsruhe.de</email>
    </contact>
    <investigator>
      <last_name>Gerhard Schymik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Koln</name>
      <address>
        <city>Koln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Wahlers, MD</last_name>
      <phone>+49221 478 32507</phone>
      <email>thorsten.wahlers@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Thorsten Wahlers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <phone>+39 049821 2585</phone>
      <email>giuseppe.tarantini.1@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Spence, MD</last_name>
      <phone>+44 7710475449</phone>
      <email>marks.spence@belfasttrust.hscni.net; markspence1@yahoo.co.uk</email>
    </contact>
    <investigator>
      <last_name>Mark Spence, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Wendler, MD</last_name>
      <phone>+44 203 299 4341</phone>
      <email>olaf.wendler@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Olaf Wendler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London St. Thomas's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martyn Thomas, MD</last_name>
      <phone>+44 207 188 10 97</phone>
      <email>martyn.thomas@gstt.nhs.uk; mttwins@aol.com</email>
    </contact>
    <investigator>
      <last_name>Martyn Thomas, MD`</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The London Heart Hospital</name>
      <address>
        <city>London</city>
        <zip>W1G 8PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mullen, MD</last_name>
      <phone>+44 207 504 8801</phone>
      <email>MichaeI.Mullen@uclh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Michael Mullen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalrymple-Hay, MD</last_name>
      <phone>+44 1752 439231</phone>
      <email>malcolm@dalrymple-hay.com</email>
    </contact>
    <investigator>
      <last_name>mple-Hay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 27, 2013</lastchanged_date>
  <firstreceived_date>March 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Aortic Stenosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
